Pure mucinous adenocarcinoma of the breast with the rare lymphoplasmacytic infiltration: A case report with review of literature
We present the case of a 55-year-old female with a 15-year history of a painless, gradually enlarging palpable lump on her left breast. Upon examination, a 5  × 5 cm lump with well-defined margins and a hard consistency was found in the lower outer quadrant of the left breast. Histopathological examination confirmed a diagnosis of Mucinous Adenocarcinoma of the Left Breast. The patient underwent modified radical mastectomy and received adjuvant endo crine therapy with tamoxifen due to hormone receptor-positive status. Mucinous carcinoma of the breast is a unique entity with specific histological features including the...
Source: Clinical Case Reports - March 27, 2024 Category: General Medicine Authors: Yash Hasmukhbhai Prajapati, Vishal Bhabhor, Kahan Samirkumar Mehta, Mithoon Barot, Husen Boriwala, Mohamed Omar Tags: CASE REPORT Source Type: research

Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center
The addition of a boost to the lumpectomy bed after whole-breast (WB) radiotherapy plays a key role in the treatment of patients with breast cancer (BC). The clinical benefits of a boost with high-dose-rate brachytherapy (HDR-BT) after conventional fractionation is supported by a large body of evidence. However, few studies have described its outcomes after a hypofractionated scheme. (Source: Brachytherapy)
Source: Brachytherapy - March 23, 2024 Category: Cancer & Oncology Authors: Ana Aurora D íaz-Gavela, Elia del Cerro Peñalver, Sofía Sanchez-Garcia, Eduardo Pardo-Perez, Israel John Thuissard-Vasallo, Cristina Andreu-Vázquez, María Yolanda Molina López, Marina Pena Huertas, Luis Leonardo Guerrero-Gómez, David Sanz-Rosa, Fel Tags: Original Research Source Type: research

Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study
CONCLUSIONS: The treatment of breast cancer cell lines with anti-cancer drugs in combination with secretome isolated from molecular subtype specific CAFs, reduced the cytotoxic effect of the drugs. In addition, LCMS data also highlighted different composition of secreted proteins from different breast cancer associated fibroblasts. Thus, TME has heterogenous population of CAFs across the breast cancer subtypes and in vitro experiments highlight their contribution to chemotherapy resistance which needs further validation.PMID:38517765 | DOI:10.3233/BD-230011 (Source: Breast Disease)
Source: Breast Disease - March 22, 2024 Category: Cancer & Oncology Authors: Dharambir Kashyap Shalmoli Bhattacharya Santosh Irinike Siddhant Khare Ashim Das Gurpreet Singh Amanjit Bal Source Type: research

Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer
CONCLUSION: Among men ≥ 65 years old with T1-2N0 HR + breast cancer, RT alone did not confer an OS benefit over HT alone. Combination of RT + HT demonstrated significant improvements in OS. De-escalation of treatment through omission of either RT or HT at this point should be done with caution.PMID:38507145 | DOI:10.1007/s12282-024-01560-y (Source: Breast Cancer)
Source: Breast Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Kim Vo Colton Ladbury Stephanie Yoon Jose Bazan Scott Glaser Arya Amini Source Type: research

Treatment Patterns and Survival Outcomes in Patients With Breast Cancer on Medicaid, Pre- and Post-Expansion
CONCLUSIONS: Medicaid expansion in Ohio was associated with improvements in receipt of standard treatment of breast cancer and shorter TTI but not with improved survival outcomes. Future studies should elucidate the mechanisms at play.PMID:38498974 | DOI:10.6004/jnccn.2023.7104 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - March 18, 2024 Category: Cancer & Oncology Authors: Siran M Koroukian Weichuan Dong Jeffrey M Albert Uriel Kim Kirsten Eom Johnie Rose Cynthia Owusu Kristine M Zanotti Gregory Cooper Jennifer Tsui Source Type: research

Global prevalence and factors associated with preoperative depression in women undergoing breast surgery: a meta-analysis and meta-regression
ConclusionThe high prevalence of preoperative depression among women with breast cancer indicated the need for health care professionals to provide more psychological support to them. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 16, 2024 Category: Cancer & Oncology Source Type: research

Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
CONCLUSIONS: VAPBI based on 1 or ≥2 days of MIBT represents an attractive de-escalation of irradiation approach for low-risk breast cancer. Late toxicity profile appears acceptable while early oncological outcome shows encouraging local control. Longer follow-up is warranted in order to confirm these preliminary results.PMID:38460552 | DOI:10.1016/j.radonc.2024.110217 (Source: Cancer Control)
Source: Cancer Control - March 9, 2024 Category: Cancer & Oncology Authors: Jean-Michel Hannoun-Levi Marta Gimeno Morales Jocelyn Gal Javier Anchuelo Jose-Luis Guinot Miren Gastanaga Norbert Meszaros Csaba Polgar Vratislav Strnad Renaud Schiappa Cristina Gutierrez Source Type: research

Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort
CONCLUSIONS: VAPBI based on 1 or ≥2 days of MIBT represents an attractive de-escalation of irradiation approach for low-risk breast cancer. Late toxicity profile appears acceptable while early oncological outcome shows encouraging local control. Longer follow-up is warranted in order to confirm these preliminary results.PMID:38460552 | DOI:10.1016/j.radonc.2024.110217 (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 9, 2024 Category: Radiology Authors: Jean-Michel Hannoun-Levi Marta Gimeno Morales Jocelyn Gal Javier Anchuelo Jose-Luis Guinot Miren Gastanaga Norbert Meszaros Csaba Polgar Vratislav Strnad Renaud Schiappa Cristina Gutierrez Source Type: research

Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ
CONCLUSION: In a cohort who had DCIS diagnosis before mastectomy and were mostly symptomatic, the upgrade rate was 51.3%. Despite the high upgrade rate, nodal involvement remained comparable. Risk factors could select patients for omission of upfront SLNB, with a delayed SLNB planned if needed.PMID:38458843 | DOI:10.1016/j.clbc.2024.02.002 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Jinnie Pang Zhiyan Yan Qing Ting Tan John C Allen Mingjia Wang Geok Hoon Lim Source Type: research

Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ
CONCLUSION: In a cohort who had DCIS diagnosis before mastectomy and were mostly symptomatic, the upgrade rate was 51.3%. Despite the high upgrade rate, nodal involvement remained comparable. Risk factors could select patients for omission of upfront SLNB, with a delayed SLNB planned if needed.PMID:38458843 | DOI:10.1016/j.clbc.2024.02.002 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Jinnie Pang Zhiyan Yan Qing Ting Tan John C Allen Mingjia Wang Geok Hoon Lim Source Type: research

Out-of-pocket cost modeling of adjuvant antiestrogen and radiation therapy after lumpectomy for early-stage breast cancer across Medicaid and Medicare plans
CONCLUSIONS: This model (based on actual cost estimates per insurance plan rather than claims data) by estimating expenses within Medicare and Medicaid plans provides a level of transparency to patient cost. With knowledge of the costs borne by patients themselves, treatment decisions informed by patients' individual priorities and preferences may be further enhanced.PMID:38432284 | DOI:10.1016/j.ijrobp.2024.02.040 (Source: Health Physics)
Source: Health Physics - March 3, 2024 Category: Physics Authors: Victoria S Wu Martha Khlopin Manjeet Chadha Demetria J Smith-Graziani Reshma Jagsi Shearwood McClelland Source Type: research